TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25967368

Group type: EXPERIMENTAL
Intervention: Sedentary behaviour
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Light-lifestyle physical activity
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Moderate-vigorous physical activity (MVPA)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Modified Shuttle Test (MST) performance
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Quality of Life - Social Functioning (QOL-B)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Quality of Life - Respiratory Symptoms (QOL-B)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Decisional balance 'pros' score
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Forced expiratory volume in one-second percentage predicted (FEV1% predicted)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Disease severity
Number of subjects: 63
Study: 25967578

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 1
Study: 25967993

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen treatment (HBOT)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Baseline blood values
Number of subjects: 114
Study: 25968087

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 25968306

Group type: EXPERIMENTAL
Intervention: Higher testosterone levels
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Testosterone level
Number of subjects: 211
Study: 25968622

Group type: EXPERIMENTAL
Intervention: Laparoscopic bilateral adrenalectomy (LBA)
Number of subjects: 28
Study: 25968826

Group type: EXPERIMENTAL
Intervention: Erlotinib (150 mg orally once daily) added to concurrent chemoradiotherapy (IMRT 63 Gy/35 fractions, chemotherapy with paclitaxel 45 mg/m² and carboplatin AUC=2 for 7 weeks)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Erlotinib (150 mg orally once daily) added to concurrent chemoradiotherapy
Number of subjects: 48
Study: 25969178

Group type: EXPERIMENTAL
Intervention: Vaginal Gel
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Oral Tablets
Number of subjects: 144
Study: 25969545

Group type: EXPERIMENTAL
Intervention: Supera stent (interwoven-wire design)
Number of subjects: 264
Study: 25969833

Group type: EXPERIMENTAL
Intervention: Reserpine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Statistical model without pharmacodynamics
Number of subjects: 0
Study: 25970800

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 11466

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 11466

Group type: COMPARATOR
Intervention: Ustekinumab
Number of subjects: 11466

Group type: COMPARATOR
Intervention: Etanercept
Number of subjects: 11466

Group type: COMPARATOR
Intervention: Nonmethotrexate/nonbiologics
Number of subjects: 11466

Group type: COMPARATOR
Intervention: Methotrexate/nonbiologics
Number of subjects: 11466

Group type: EXPERIMENTAL
Intervention: Overall treatment cohorts
Number of subjects: 11466
Study: 25971341

Group type: EXPERIMENTAL
Intervention: Prognostic markers for outcome prediction in anoxic coma
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Covariates adjusted for age and sex
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Mixed effects regression models (fixed and random effects)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Null hypothesis testing
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Simon's two-stage design
Number of subjects: 172
Study: 25971721

Group type: EXPERIMENTAL
Intervention: Enteral protein intake ≥60% of the prescribed goal
Number of subjects: 1245

Group type: COMPARATOR
Intervention: Enteral protein intake <20% of the prescribed goal
Number of subjects: 1245

Group type: EXPERIMENTAL
Intervention: Mean enteral protein delivery
Number of subjects: 1245
Study: 25971791

Group type: EXPERIMENTAL
Intervention: Survey of anaesthesia staff regarding perceived barriers to documentation
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Survey of anaesthesia staff regarding institutional management of data
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Survey of anaesthesia staff regarding attitudes towards data usefulness
Number of subjects: 55
Study: 25971886

Group type: EXPERIMENTAL
Intervention: Single-dose dexmedetomidine (DMT) 0.25 μg/kg in Group O (old age group)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Single-dose dexmedetomidine (DMT) 0.35 μg/kg in Group Y (young age group)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Single-dose dexmedetomidine (DMT)
Number of subjects: 42
Study: 25972018

Group type: EXPERIMENTAL
Intervention: Laser acupuncture
Number of subjects: 104

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 104
Study: 25972188

Group type: EXPERIMENTAL
Intervention: Dilution testing using Determine™ rapid diagnostic test at 1/160 dilution
Number of subjects: 2895

Group type: COMPARATOR
Intervention: RDT diagnostic algorithm
Number of subjects: 2895
Study: 25972258

Group type: EXPERIMENTAL
Intervention: Fundus Autofluorescence Imaging (FAF) and Near Infrared (NIR) reflectance imaging
Number of subjects: 36
Study: 25972523

Group type: EXPERIMENTAL
Intervention: Midupper Arm Circumference (MUAC)
Number of subjects: 721

Group type: EXPERIMENTAL
Intervention: Midupper Arm Circumference z score (MUACZ)
Number of subjects: 721

Group type: COMPARATOR
Intervention: Weight-for-age z score (WAZ)
Number of subjects: 721

Group type: COMPARATOR
Intervention: Weight-for-length z score (WLZ)
Number of subjects: 721
Study: 25972528

Group type: EXPERIMENTAL
Intervention: Maternal dietary choline intake
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Maternal plasma concentrations of betaine, dimethylglycine, and TMAO
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Maternal dietary intake and fetal genetic variants
Number of subjects: 368
Study: 25972901

Group type: EXPERIMENTAL
Intervention: Vandetanib (67-150 mg/m²/day)
Number of subjects: 13
Study: 25973150

Group type: EXPERIMENTAL
Intervention: Quercetin 250 mg capsules (bid)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 30
Study: 25973421

Group type: EXPERIMENTAL
Intervention: Primary transposed brachio-basilic vein (TBBV) fistula
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Staged TBBV fistula
Number of subjects: 16

Group type: COMPARATOR
Intervention: Primary TBBV fistula
Number of subjects: 16
Study: 25973678

Group type: EXPERIMENTAL
Intervention: Foaming facial wash and SPF 30 moisturizer
Number of subjects: 35
Study: 25974030

Group type: EXPERIMENTAL
Intervention: Linagliptin added to basal insulin
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Linagliptin
Number of subjects: 247
Study: 25974235

Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cell therapy
Number of subjects: 0
Study: 25974382

Group type: EXPERIMENTAL
Intervention: Lenalidomide, dexamethasone and cyclophosphamide
Number of subjects: 28
Study: 25975390

Group type: EXPERIMENTAL
Intervention: Intravenous propofol anesthesia clinically titrated by providers blinded to BIS
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Proposed maintenance dosing regimen targeting BIS of 50 ± 10
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: PK/PD models for children/obese adults (PK:Eleveld/PD:Cortinez)
Number of subjects: 26
Study: 25975429

Group type: EXPERIMENTAL
Intervention: DASH
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: LEFS
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: PSFS
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: WPAI: SHP (daily activities impairment portion)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: PGIC
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: PGAR
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: SF-36
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Grip strength
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Walking speed
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Swelling
Number of subjects: 20
Study: 25975848

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT)
Number of subjects: 111
Study: 25975934

Group type: EXPERIMENTAL
Intervention: 750 mg telaprevir every 8 hours for 6 days
Number of subjects: 24

Group type: COMPARATOR
Intervention: Healthy control volunteers
Number of subjects: 24
Study: 25975975

Group type: EXPERIMENTAL
Intervention: Idarubicin with ATRA (PETHEMA/HOVON cohort)
Number of subjects: 525

Group type: COMPARATOR
Intervention: Daunorubicin with ATRA (IC-APL cohort)
Number of subjects: 525
Study: 25976268

Group type: EXPERIMENTAL
Intervention: PED-based smoking cessation intervention (counseling, referral to Quitline, free nicotine replacement therapy)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: PED-based smoking cessation intervention
Number of subjects: 200
Study: 25976713

Group type: EXPERIMENTAL
Intervention: eVLU (internet-based learning program)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 0
Study: 25976760

Group type: EXPERIMENTAL
Intervention: Experiences of intimate partner violence (IPV) after HIV infection
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Pathways leading to IPV
Number of subjects: 19
Study: 25976768

Group type: EXPERIMENTAL
Intervention: Chemotherapy (first and second courses)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Chemotherapy (multiple courses)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: MIP-3α biomarker
Number of subjects: 50

Group type: COMPARATOR
Intervention: Healthy controls (untreated)
Number of subjects: 50
Study: 25977111

Group type: COMPARATOR
Intervention: Coronary CT angiography (CTA) alone
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Combined coronary CT angiography (CTA) and myocardial CT perfusion (CTP)
Number of subjects: 381
Study: 25977197

Group type: EXPERIMENTAL
Intervention: MyBehavior's personalized suggestions (n=9)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Nonpersonalized suggestions (n=8)
Number of subjects: 17
Study: 25977266

Group type: EXPERIMENTAL
Intervention: Daclatasvir (60 mg once daily), asunaprevir (100 mg twice daily), peg-IFN/RBV after a 4-week lead-in phase with peg-IFN/RBV for a total of 24 weeks.
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Daclatasvir, asunaprevir, peg-IFN/RBV
Number of subjects: 75
Study: 25977304

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 25977463

Group type: EXPERIMENTAL
Intervention: (18)F-FDG PET/CT
Number of subjects: 25
Study: 25977584

Group type: EXPERIMENTAL
Intervention: iC9-T cells
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: AP1903 (CID)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CID
Number of subjects: 12
Study: 25977882

Group type: EXPERIMENTAL
Intervention: (68)Ga-DOTA-peptides PET/CT
Number of subjects: 27
Study: 25977884

Group type: EXPERIMENTAL
Intervention: Lapatinib (1,500 mg once daily for 8 days)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Baseline scan
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Day 8 scan
Number of subjects: 6
Study: 25978152

Group type: EXPERIMENTAL
Intervention: 8-hour shifts
Number of subjects: 1

Group type: COMPARATOR
Intervention: 24-hour shifts
Number of subjects: 1
Study: 25979098

Group type: EXPERIMENTAL
Intervention: BIS 65-75 (light sedation)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: BIS 50-60 (deep sedation)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: BIS-guided propofol infusion
Number of subjects: 108
Study: 25979109

Group type: EXPERIMENTAL
Intervention: Inflamed colonic inflammatory bowel disease (IBD) mucosa
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TNBS colitis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inflamed samples
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Expression of GUCA2A and GUCY2C
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transcription factor CDX2
Number of subjects: 0
Study: 25979230

Group type: EXPERIMENTAL
Intervention: Curcumin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Curcumin + FOLFOX chemotherapy
Number of subjects: 12
Study: 25979390

Group type: EXPERIMENTAL
Intervention: Novel immune-specific systemic therapies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-throughput sequencing technologies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Discovery of human papillomavirus
Number of subjects: 0
Study: 25979539

Group type: EXPERIMENTAL
Intervention: Informed of high-risk status by health professional
Number of subjects: 59

Group type: COMPARATOR
Intervention: Not informed of high-risk status by health professional
Number of subjects: 59
Study: 25979786

Group type: EXPERIMENTAL
Intervention: Supportive text messages (twice-daily for 3 months, then daily for 3 months)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no text messages)
Number of subjects: 120
Study: 25979867

Group type: EXPERIMENTAL
Intervention: Telemedicine consultation system for intravenous thrombolysis
Number of subjects: 300

Group type: COMPARATOR
Intervention: Usual stroke care quality in spoke hospitals without guidance from the hub hospital
Number of subjects: 300
Study: 25980594

Group type: EXPERIMENTAL
Intervention: Vemurafenib 240-1120 mg or 960 mg orally twice daily
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Vemurafenib continued after local therapy
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Vemurafenib treatment duration beyond initial PD
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Vemurafenib monotherapy
Number of subjects: 48
Study: 25980753

Group type: COMPARATOR
Intervention: Lugol's chromoendoscopy (LCE)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Lugol's chromoendoscopy (LCE) + High-Resolution Microendoscope (HRME)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: High-Resolution Microendoscope (HRME)
Number of subjects: 147
Study: 25980755

Group type: EXPERIMENTAL
Intervention: Delayed gastric emptying (GE)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: DCCT baseline HbA1c
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Duration of DM before DCCT
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Mean HbA1c during DCCT-EDIC
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Retinopathy
Number of subjects: 78

Group type: COMPARATOR
Intervention: Normal gastric emptying
Number of subjects: 78

Group type: COMPARATOR
Intervention: Delayed gastric emptying
Number of subjects: 78

Group type: COMPARATOR
Intervention: Rapid gastric emptying
Number of subjects: 78
Study: 25981169

Group type: EXPERIMENTAL
Intervention: Neoadjuvant erlotinib in patients with mutant EGFR
Number of subjects: 24

Group type: COMPARATOR
Intervention: Gemcitabine/carboplatin (GC) in patients with wild type EGFR
Number of subjects: 24
Study: 25981490

Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccination (Havrix(®) junior; GSK Vaccines, Belgium) with a two-dose schedule
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Hospital-based active surveillance for hepatitis cases
Number of subjects: 42
Study: 25981554

Group type: EXPERIMENTAL
Intervention: Gene-expression classifier
Number of subjects: 639

Group type: EXPERIMENTAL
Intervention: Gene-expression classifier plus bronchoscopy
Number of subjects: 639
Study: 25981814

Group type: EXPERIMENTAL
Intervention: Dovitinib (500 mg per day, orally, on a 5-days-on and 2-days-off schedule)
Number of subjects: 53
Study: 25981813

Group type: EXPERIMENTAL
Intervention: Vismodegib 150 mg oral capsules once a day on a continuous basis in 28-day cycles
Number of subjects: 1227
Study: 25982012

Group type: EXPERIMENTAL
Intervention: Vandetanib and everolimus
Number of subjects: 1
Study: 25982504

Group type: EXPERIMENTAL
Intervention: Methylcobalamin (30 mg/kg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 20
Study: 25982653

Group type: EXPERIMENTAL
Intervention: Renal denervation (RDN) using the Symplicity Flex™ catheter
Number of subjects: 63
Study: 25982652

Group type: EXPERIMENTAL
Intervention: Symplicity multi-electrode radiofrequency renal denervation system
Number of subjects: 50
Study: 25982654

Group type: EXPERIMENTAL
Intervention: Intravascular prosthesis implant
Number of subjects: 1
Study: 25983041

Group type: EXPERIMENTAL
Intervention: SB939 60 mg on alternate days three times per week for 3 weeks on a 4-week cycle
Number of subjects: 32
Study: 25984873

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy for 6.5 years
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 25984876

Group type: EXPERIMENTAL
Intervention: Rapid intraarterial treatment plus usual care
Number of subjects: 0
Study: 25984880

Group type: EXPERIMENTAL
Intervention: 6 weeks of antibiotics
Number of subjects: 0

Group type: COMPARATOR
Intervention: 12 weeks of antibiotics
Number of subjects: 0
Study: 25985024

Group type: EXPERIMENTAL
Intervention: Inguinal hernia repair
Number of subjects: 2929

Group type: EXPERIMENTAL
Intervention: Vaginal hysterectomy
Number of subjects: 2929

Group type: EXPERIMENTAL
Intervention: Abdominal hysterectomy
Number of subjects: 2929

Group type: EXPERIMENTAL
Intervention: Thoracotomy
Number of subjects: 2929

Group type: COMPARATOR
Intervention: CPSP risk model
Number of subjects: 2929
Study: 25985169

Group type: EXPERIMENTAL
Intervention: Hypothermia induced by rapid infusion of 600-2000 mL cold saline combined with endovascular cooling
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Hypothermia treatment
Number of subjects: 140

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 140
Study: 25985404

Group type: EXPERIMENTAL
Intervention: Efavirenz-based antiretroviral therapy (ART)
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Lopinavir-based antiretroviral therapy (ART)
Number of subjects: 325
Study: 25985774

Group type: EXPERIMENTAL
Intervention: Formal provider care seeking for eclampsia
Number of subjects: 9576

Group type: EXPERIMENTAL
Intervention: Formal provider care seeking for hemorrhage
Number of subjects: 9576

Group type: EXPERIMENTAL
Intervention: Formal provider care seeking for obstructed labor
Number of subjects: 9576

Group type: EXPERIMENTAL
Intervention: Formal provider care seeking for sepsis
Number of subjects: 9576

Group type: EXPERIMENTAL
Intervention: Overall care seeking behavior
Number of subjects: 9576

Group type: EXPERIMENTAL
Intervention: Socioeconomic factors associated with care seeking from formal providers
Number of subjects: 9576

Group type: EXPERIMENTAL
Intervention: Service factors associated with care seeking from formal providers
Number of subjects: 9576
Study: 25985785

Group type: COMPARATOR
Intervention: Guidewire and microcatheter strategy
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Specialized CTO crossing device
Number of subjects: 438
Study: 25985870

Group type: EXPERIMENTAL
Intervention: Propofol as the sole induction agent
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Propofol as the primary maintenance agent
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Propofol infusion rates
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Propofol infusion duration
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Total doses of propofol
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Adverse events related to propofol
Number of subjects: 28
Study: 25985882

Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (AA) plus prednisone with concomitant bone-targeted therapy (BTT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prednisone alone
Number of subjects: 0
Study: 25986244

Group type: EXPERIMENTAL
Intervention: Sorafenib 400 mg b.i.d. and bortezomib 1.0 mg/m2 weekly for 3 of 4 weeks
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Sorafenib and bortezomib combination
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Highest dose level of sorafenib and bortezomib
Number of subjects: 11
Study: 25986629

Group type: EXPERIMENTAL
Intervention: Threshold suspend (TS) feature of sensor-augmented insulin pump (SAP) therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 25986784

Group type: EXPERIMENTAL
Intervention: Active transcranial direct current stimulation (tDCS) at 1 mA for 20 minutes
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 60
Study: 25987537

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulins (IVIG) as an adjunct to standard treatment
Number of subjects: 34

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 34

Group type: COMPARATOR
Intervention: Non-SC control group
Number of subjects: 34
Study: 25987590

Group type: EXPERIMENTAL
Intervention: Surpass flow diverter
Number of subjects: 20
Study: 25987620

Group type: EXPERIMENTAL
Intervention: Cycloserine (250 mg), p-aminosalicylic acid (PAS) (5.28 g), prothionamide (250 mg) twice daily, pyrazinamide (1,500 mg) once daily, levofloxacin (750 mg) once daily, streptomycin (1 g) once daily
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Cycloserine (250 mg), p-aminosalicylic acid (PAS) (5.28 g), prothionamide (250 mg) twice daily, pyrazinamide (1,500 mg) once daily, moxifloxacin (400 mg) once daily, kanamycin (1 g) once daily
Number of subjects: 16
Study: 25987775

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF)
Number of subjects: 516
Study: 25987791

Group type: EXPERIMENTAL
Intervention: Cholecalciferol 100000 IU per week for 4 weeks followed by 100000 IU per month in combination with PegIFN/RBV for 12 months.
Number of subjects: 32
Study: 25988359

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UFH) with clopidogrel
Number of subjects: 1063

Group type: COMPARATOR
Intervention: Enoxaparin with clopidogrel
Number of subjects: 1063

Group type: EXPERIMENTAL
Intervention: UFH alone
Number of subjects: 1063

Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 1063
Study: 25989179

Group type: EXPERIMENTAL
Intervention: White button mushroom (WBM) powder, dosage of 8 g/d and 14 g/d
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: White button mushroom (WBM) powder
Number of subjects: 36
Study: 25989324

Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 14
Study: 25989594

Group type: EXPERIMENTAL
Intervention: Bronchodilation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (healthy volunteers)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Measuring 12 third- or fourth-generation airways
Number of subjects: 20
Study: 25989829

Group type: EXPERIMENTAL
Intervention: Etravirine (ETR) 400 mg for 8 weeks after switching from bPI or EFV
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Etravirine (ETR)
Number of subjects: 31
Study: 25989973

Group type: EXPERIMENTAL
Intervention: Administration of FSFI during menstruation
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Administration of FSFI between menses
Number of subjects: 33